Page last updated: 2024-08-24

triazoles and Thalassemia

triazoles has been researched along with Thalassemia in 75 studies

Research

Studies (75)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (20.00)	29.6817
2010's	54 (72.00)	24.3611
2020's	6 (8.00)	2.80

Authors

Authors	Studies
Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J	1
Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ	1
Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V	1
Allò, M; Campisi, S; Casale, M; Cassinerio, E; Cattoni, A; De Michele, E; Di Concilio, R; Ferrara, F; Forni, GL; Ladogana, S; Lazzarino, AI; Marcon, A; Notarangelo, LD; Origa, R; Pasquali, D; Peluso, A; Perrotta, S; Picariello, S; Poggi, M; Putti, MC; Quarta, A; Renni, R; Roberti, D; Sau, A; Serra, M; Sportelli, F; Sturiale, P; Tartaglione, I	1
Chhabra, IK; Ibrahim, HM; Mohammed, NS; Shafie, AA; Wong, JHY	1
Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ	1
Ambrogio, AG; Baldini, M; Cassinerio, E; Mancarella, M; Marcon, A; Motta, I	1
Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK	1
Kolnagou, A; Kontoghiorghes, GJ	1
Aydogdu, S; Bayramoglu, Z; Dursun, M; Karagenc, AO; Karakas, Z; Karaman, S; Tugcu, D; Yilmaz, Y	1
Sivaramakrishnan, G; Sridharan, K	1
Sari, TT; Wahidiyat, PA; Yosia, M	1
Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y	1
Pongtanakul, B; Viprakasit, V	1
Kontoghiorghes, GJ	4
Brittenham, GM; Olivieri, NF	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z	1
Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ	1
Cappellini, MD; Taher, AT; Temraz, S	1
Habr, D; Huang, SL; Lai, YR; Li, CF; Li, Q; Liu, RR; Martin, N; Shen, ZX	1
Huang, L; Jiang, H; Xia, S; Zhang, W	1
Cappellini, MD; Chuncharunee, S; Habr, D; Karakas, Z; Kattamis, A; Origa, R; Porter, JB; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhu, Z	2
Plosker, GL; Shirley, M	1
Atipas, S; Kusuwan, T; Limviriyakul, S; Pooliam, J; Sangpraypan, T; Tanphaichitr, A; Tanphaichitr, VS; Viprakasit, V	1
Haghpanah, S; Karimi, M	1
Chuang, GT; Lu, MY; Tsai, IJ; Tsau, YK	1
Adil, SN; Shaikh, MS	1
Bottaro, G; Clementi, E; Deodato, F; Dionisi-Vici, C; Falvella, FS; Goffredo, B; Marano, M; Marinaro, AM; Pisani, M; Stoppa, F	1
Marsella, M; Ricchi, P	1
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S	1
Aydinok, Y; Cappellini, MD; Joaquin, V; Karakas, Z; Kattamis, A; Lai, YR; Porter, JB; Siritanaratkul, N; Taher, AT; Uwamahoro, MJ; Viprakasit, V; Wang, C; Zhu, Z	1
Kontoghiorghe, CN; Kontoghiorghes, GJ	1
Gomber, S; Jain, P; Narang, M; Sharma, S	1
Beydoun, HG; Saliba, AN; Taher, AT	1
Deghedy, MR; Ebeid, WM; El-Shazly, AA; Elkitkat, RS	1
Chuansumrit, A; Kadegasem, P; Khlairit, P; Mahachoklertwattana, P; Pengpis, P; Poomthavorn, P; Sirachainan, N; Sungkarat, W; Wongwerawattanakoon, P	1
Aydinok, Y; El-Ali, A; El-Beshlawy, A; Elalfy, M; Han, J; Lee, SH; Porter, JB; Sutcharitchan, P; Taher, A	1
Cappellini, MD; Kattamis, A; Porter, JB; Taher, AT; Viprakasit, V	1
Cortoos, A; Goh, AS; Huang, V; Kattamis, A; Kourakli, A; Merino Herranz, R; Origa, R; Perrotta, S; Porter, JB; Ruffo, GB; Taher, AT; Weill, M	1
Barada, K; Khalife, M; Musallam, KM; Taher, AT	1
Chan, GC; Chan, S; Ha, SY; Ho, PL	1
Efstathiou, A; Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ; Michaelides, Y	1
Cappellini, MD; Taher, A	1
Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V	1
Agarwal, MB	1
Jetsrisuparb, A; Jetsrisuparb, C; Komvilaisak, P; Wiangnon, S	1
Hershko, C	1
Porter, JB; Shah, FT	1
Berdoukas, V; Coates, T; Farmaki, K; Wood, JC	1
Bowden, DK; Chan, LL; Chiu, CF; Domokos, G; Ha, SY; Habr, D; Ho, PJ; Ibrahim, H; Li, CK; Lin, KH; Roubert, B; Sutcharitchan, P; Viprakasit, V; Xue, HL	1
Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R	1
Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R	1
Kohli, S; Saxena, R; Verma, IC	1
Pankaew, T; Torcharus, K	1
Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G	1
De Francia, S; Di Carlo, F; Massano, D; Piccione, FM; Piga, A; Pirro, E; Racca, S	1
Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ	1
Gaur, A	1
Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, J; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y	1
Marks, PW	1
Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT	1
Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E	1
Nathan, DG	1
Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ	1
Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G	1
Fischer, R; Harmatz, P; Nielsen, P; Piga, A	1
Dubey, AP; Parakh, A; Sudha, S	1
Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E	1
Berdoukas, V; Modell, B	1
Humbert, H; Mangoni, P; Marfil, F; Maurer, G; Rouan, MC; Séchaud, R	1

Reviews

23 review(s) available for triazoles and Thalassemia

Article	Year
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in bioscience (Elite edition), 2022, 07-12, Volume: 14, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Risk Assessment; Thalassemia; Triazoles	2022
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2017, 08-15, Volume: 8 Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferiprone; Deferoxamine; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Patient Satisfaction; Pyridones; Randomized Controlled Trials as Topic; Thalassemia; Triazoles	2017
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6 Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Silymarin; Thalassemia; Triazoles	2018
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta medica Indonesiana, 2018, Volume: 50, Issue:2 Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; Indonesia; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Pyridones; Thalassemia; Triazoles	2018
Management of the thalassemias. Cold Spring Harbor perspectives in medicine, 2013, Jun-01, Volume: 3, Issue:6 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Pancreas; Pituitary Gland, Anterior; Pyridones; Thalassemia; Triazoles	2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Thalassemia; Transfusion Reaction; Triazoles	2013
Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert review of hematology, 2013, Volume: 6, Issue:5 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Triazoles	2013
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PloS one, 2013, Volume: 8, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Stroke Volume; Thalassemia; Treatment Outcome; Triazoles	2013
Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Drugs, 2014, Volume: 74, Issue:9 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles	2014
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2015, Volume: 9 Topics: Benzoates; Biomarkers; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Syndrome; Thalassemia; Treatment Outcome; Triazoles	2015
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Syndrome; Thalassemia; Triazoles	2016
Deferasirox: oral, once daily iron chelator--an expert opinion. Indian journal of pediatrics, 2010, Volume: 77, Issue:2 Topics: Benzoates; Cardiovascular Diseases; Chelating Agents; Deferasirox; Expert Testimony; Hemosiderosis; Humans; Iron; Liver; Thalassemia; Triazoles	2010
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2010
Past, present & future scenario of thalassaemic care & control in India. The Indian journal of medical research, 2011, Volume: 134 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; India; Male; Preimplantation Diagnosis; Prenatal Diagnosis; Pyridones; Thalassemia; Triazoles	2011
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2 Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Randomized Controlled Trials as Topic; Thalassemia; Triazoles	2012
Iron mobilization using chelation and phlebotomy. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2012, Volume: 26, Issue:2-3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Phlebotomy; Pyridones; Thalassemia; Triazoles	2012
Clinical research: a tale of two studies. Transactions of the American Clinical and Climatological Association, 2003, Volume: 114 Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug Industry; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Triazoles	2003
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles	2005
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Monitoring; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Pyridones; Retrospective Studies; Thalassemia; Triazoles	2005
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles	2006
Deferasirox: the new oral iron chelator. Indian pediatrics, 2007, Volume: 44, Issue:8 Topics: Benzoates; Child; Child, Preschool; Deferasirox; Humans; Iron Chelating Agents; Thalassemia; Triazoles	2007
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2008

Trials

15 trial(s) available for triazoles and Thalassemia

Article	Year
Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study. Journal of pharmacy practice, 2023, Volume: 36, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Triazoles	2023
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. American journal of hematology, 2013, Volume: 88, Issue:6 Topics: Adult; Benzoates; Deferasirox; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Thalassemia; Triazoles; Young Adult	2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of hematology, 2013, Volume: 92, Issue:11 Topics: Benzoates; Blood Transfusion; Cross-Over Studies; Deferasirox; Double-Blind Method; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Time Factors; Treatment Outcome; Triazoles	2013
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. Transfusion medicine (Oxford, England), 2013, Volume: 23, Issue:6 Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Benzoates; Child; Child, Preschool; China; Deferasirox; Female; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Thalassemia; Triazoles	2013
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. European journal of haematology, 2014, Volume: 92, Issue:6 Topics: Benzoates; Deferasirox; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles	2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. British journal of haematology, 2015, Volume: 168, Issue:2 Topics: Adolescent; Adult; Benzoates; Deferasirox; Double-Blind Method; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Thalassemia; Triazoles; Young Adult	2015
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood cells, molecules & diseases, 2016, Volume: 57 Topics: Adolescent; Adult; Benzoates; Blood Transfusion; Chelation Therapy; Child; Deferasirox; Diarrhea; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Nausea; Thalassemia; Treatment Outcome; Triazoles	2016
Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia. Acta haematologica, 2017, Volume: 137, Issue:1 Topics: Adolescent; Benzoates; Blood Glucose; Blood Transfusion; Chelation Therapy; Deferasirox; Drug Administration Schedule; Fasting; Female; Ferritins; Glucose Tolerance Test; Humans; Insulin Resistance; Insulin-Secreting Cells; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2017
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. European journal of haematology, 2017, Volume: 98, Issue:3 Topics: Adolescent; Adult; Benzoates; Biomarkers; Chelation Therapy; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Prognosis; ROC Curve; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. American journal of hematology, 2017, Volume: 92, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chemistry, Pharmaceutical; Child; Deferasirox; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Quality of Life; Tablets, Enteric-Coated; Thalassemia; Triazoles; Young Adult	2017
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, Volume: 95, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult	2010
Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International journal of hematology, 2011, Volume: 93, Issue:3 Topics: Adolescent; Adult; Asia, Southeastern; Benzoates; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Thalassemia; Triazoles	2011
Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Indian pediatrics, 2012, Volume: 49, Issue:4 Topics: Adolescent; Benzoates; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Thalassemia; Triazoles; Young Adult	2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, Aug-02, Volume: 120, Issue:5 Topics: Adolescent; Adult; Aged; Algorithms; Benzoates; Blood Transfusion; Child; Deferasirox; Double-Blind Method; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Placebos; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2012
Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood cells, molecules & diseases, 2013, Volume: 50, Issue:2 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Pilot Projects; Thalassemia; Transferrin; Triazoles; Young Adult	2013

Other Studies

37 other study(ies) available for triazoles and Thalassemia

Article	Year
Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatrics international : official journal of the Japan Pediatric Society, 2021, Volume: 63, Issue:4 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles	2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica, 2022, 02-01, Volume: 107, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Risk Assessment; Risk Factors; Thalassemia; Triazoles	2022
Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective. Orphanet journal of rare diseases, 2021, 04-07, Volume: 16, Issue:1 Topics: Benzoates; Blood Transfusion; Cost of Illness; Cross-Sectional Studies; Deferasirox; Deferoxamine; Humans; Malaysia; Quality of Life; Thalassemia; Triazoles	2021
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc	2021
Adrenal insufficiency: An emerging challenge in thalassemia? American journal of hematology, 2017, Volume: 92, Issue:6 Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Adult; Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Hypoglycemia; Hypogonadism; Hypothalamo-Hypophyseal System; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelolipoma; Pituitary-Adrenal System; Shock, Septic; Thalassemia; Triazoles	2017
Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in bioscience (Landmark edition), 2018, 01-01, Volume: 23, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2018
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. La Radiologia medica, 2018, Volume: 123, Issue:8 Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; Deferiprone; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pyridones; Retrospective Studies; Thalassemia; Treatment Outcome; Triazoles; Turkey	2018
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2013, Volume: 112, Issue:4 Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Iron Overload; Markov Chains; Quality-Adjusted Life Years; Thalassemia; Transfusion Reaction; Triazoles	2013
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood cells, molecules & diseases, 2013, Volume: 51, Issue:2 Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Transfusion Reaction; Treatment Outcome; Triazoles	2013
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Marketing; Patient Safety; Pyridones; Thalassemia; Triazoles	2013
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Developing Countries; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Incidence; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thailand; Thalassemia; Transfusion Reaction; Triazoles; Young Adult	2014
The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran. Health policy (Amsterdam, Netherlands), 2015, Volume: 119, Issue:2 Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Ferritins; Health Status; Hemophilia A; Humans; Internationality; Iran; Male; Plasma; Surveys and Questionnaires; Thalassemia; Triazoles; Young Adult	2015
Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Nephrology (Carlton, Vic.), 2015, Volume: 20, Issue:12 Topics: Acidosis, Renal Tubular; Adolescent; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Fanconi Syndrome; Female; Hospitals, University; Humans; Hypophosphatemia; Incidence; Iron Chelating Agents; Male; Retrospective Studies; Risk Factors; Taiwan; Thalassemia; Triazoles; Young Adult	2015
Iron Chelation in Patients with Transfusion Dependent Thalassemia: An Insight on Response to Deferasirox. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2015, Volume: 25, Issue:7 Topics: Adolescent; Benzoates; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2015
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. European journal of clinical pharmacology, 2016, Volume: 72, Issue:2 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzoates; Child, Preschool; Deferasirox; Female; Glucuronosyltransferase; Humans; Iron Chelating Agents; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymorphism, Single Nucleotide; Thalassemia; Triazoles	2016
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles	2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Indian pediatrics, 2016, Volume: 53, Issue:3 Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Pyridones; Thalassemia; Transfusion Reaction; Triazoles	2016
Deferasirox in thalassemia patients with end-stage renal disease. American journal of hematology, 2016, Volume: 91, Issue:10 Topics: Benzoates; Deferasirox; Female; Humans; Iron Chelating Agents; Kidney Failure, Chronic; Male; Middle Aged; Thalassemia; Triazoles	2016
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA. Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:6 Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Electroretinography; Evoked Potentials, Visual; Eye Diseases; Female; Humans; Iron Chelating Agents; Male; Optic Nerve; Retina; Retinal Diseases; Retrospective Studies; Siderophores; Thalassemia; Treatment Outcome; Triazoles; Visual Acuity	2017
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating Agents; Pyridones; Syndrome; Thalassemia; Triazoles	2016
Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Annals of hematology, 2009, Volume: 88, Issue:10 Topics: Antiviral Agents; Benzoates; Deferasirox; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Male; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2009
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Negative Bacterial Infections; Humans; Iron Chelating Agents; Iron Overload; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Prevalence; Pyridones; Thalassemia; Triazoles	2009
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Pyridones; Risk Assessment; Siderophores; Thalassemia; Triazoles	2009
Deferasirox (Exjade) for the treatment of iron overload. Acta haematologica, 2009, Volume: 122, Issue:2-3 Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles	2009
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:5 Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Retrospective Studies; Siderophores; Survival Rate; Thalassemia; Treatment Outcome; Triazoles; Young Adult	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; Iron Overload; Models, Molecular; Pyridones; Reactive Oxygen Species; Thalassemia; Transferrin; Transfusion Reaction; Triazoles	2010
Iron chelation in thalassemia: time to reconsider our comfort zones. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Pyridones; Survival Analysis; Thalassemia; Triazoles	2011
Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American journal of hematology, 2011, Volume: 86, Issue:5 Topics: Adolescent; Adult; Age Factors; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Medical Records; Medication Adherence; Middle Aged; North America; Retrospective Studies; Self Report; Thalassemia; Triazoles; United Kingdom; Young Adult	2011
Health-related quality of life in Thai thalassemic children treated with iron chelation. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:4 Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Emotions; Female; Health Status; Humans; Interpersonal Relations; Iron Chelating Agents; Male; Pyridones; Quality of Life; Severity of Illness Index; Social Support; Thailand; Thalassemia; Triazoles	2011
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Apr-15, Volume: 893-894 Topics: Benzoates; Chromatography, High Pressure Liquid; Deferasirox; Female; Ferritins; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Statistics, Nonparametric; Thalassemia; Triazoles	2012
Thalassemia: cardiac iron and chelators. Indian pediatrics, 2012, Volume: 49, Issue:4 Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Myocardium; Thalassemia; Triazoles; Ventricular Function, Left	2012
Iron out for nontransfused thalassemia. Blood, 2012, Aug-02, Volume: 120, Issue:5 Topics: Benzoates; Deferasirox; Female; Humans; Iron Overload; Male; Thalassemia; Triazoles	2012
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Cholelithiasis; Clinical Trials, Phase III as Topic; Creatinine; Deferasirox; Edema; Ethnicity; Female; Ferritins; Gastrointestinal Diseases; Hematologic Diseases; Hepatitis, Viral, Human; Humans; Infant; Iron; Iron Chelating Agents; Iron Overload; Kidney Diseases; Liver; Magnetic Resonance Imaging; Male; Multicenter Studies as Topic; Prospective Studies; Thalassemia; Transfusion Reaction; Triazoles; Young Adult	2013
Do we need more iron-chelating drugs? Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia; Triazoles	2003
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European journal of haematology, 2008, Volume: 80, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles	2008
Transfusion-dependent thalassaemia: a new era. The Medical journal of Australia, 2008, Jan-21, Volume: 188, Issue:2 Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles	2008
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2 Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine; Drug Stability; Humans; Hydrogen-Ion Concentration; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Reproducibility of Results; Spectrophotometry, Ultraviolet; Temperature; Thalassemia; Triazoles	2001